On May 21, METiS Pharmaceuticals declined 6.56% in regular trading, trading at HK$16.9 per share, with trading volume of HK$92.71 million. The stock has pulled back significantly from its first-day high since listing on May 13.

The decline reflects a continued post-IPO correction following the stock's 173% surge on its debut. As the world's first AI drug delivery company to go public, METiS priced its IPO at HK$10.50 per share. However, the initial euphoria has rapidly dissipated. The company remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure as early investors exit positions.

METiS is an AI-driven biotech company specializing in targeted drug delivery using its proprietary NanoForge platform. The company has developed capabilities for precision delivery across eight key organs and tissues, with 224 patent applications filed and 52 patents granted.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)